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ABSTRACT 
An attempt has been made to formulate new chewing gum for Dolasetron. The new drug delivery system was obtained, at room 
temperature conventional pharmaceutical equipment. The resulting chewing gum comprises a gum core combined with fillers, 
antioxidants, coloring agent and plasticizers, which provide smooth appearance and flexibility during storage and chewing. Drug 
release from a dosage form is the critical step in drug absorption and bioavailability, thus an experimental work has been designed to 
evaluate the efficiency of this kind of therapeutic system by verifying its capability to release the drug dose and by assessing the 
delivery of Dolasetron for bypassing the hepatic first pass effect. Simple diffusion into the medium causes the release of only a small 
percentage of the drug contained in the medicated chewing gum, while the delivery of the major part of the dose occurs during 
mastication. In the present study, an attempt has been made to formulate the chewing gum of Dolasetron. Different formulations of 
chewing gum with varying concentration of plasticizers like glycerol and castor oil were formulated. MCG II formulation was 
considered to be the best-optimized formula which consists of synthetic gum base (45%), Sorbitol (14.6%), sucrose (46%) etc. 
which shows first slow release the fast release in the phosphate buffer saline (ph 6.8). The cumulative drug release of MCG II 
formulation was found to be 99.43 %. From this study, we can conclude that the medicated chewing formulation can be a better 
choice in the coming years which provides several benefits and also benefits commercially. 
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INTRODUCTION 
Drug can be administered via different routes of 
administration to produce a systemic pharmacologic 
effect. The most common method to administer drug is 
oral route, in which the drug is swallowed and it enters 
the systemic circulation. There are various dosage forms 
those can be administered orally. Out of which, chewing 
gum is most popular. It is a potentially useful means of 
administering drugs locally and systemically. Chewing 
gum has been used for centuries to clean the mouth as 
well as fresh the breath. The advantage of buccal route is 
administration has direct access to systemic circulation. 
This avoids first pass hepatic metabolism and local loss 
of the drug at site. In the present work non toxic 
synthetic gum base has been used in the formulation of 
medicated chewing gum (MCG) containing an 
Dolasetron as an Antiemetic Agent.
1, 2
 
Dolasetron is suitable drug to prepare MCG. Dolasetron 
is a selective serotonin 5-HT3 receptor antagonist. In 
vivo, the drug is rapidly converted into its major active 
metabolite, hydrodolasetron, which seems to be largely 
responsible for the drug's pharmacological activity. The 
antiemetic activity of the drug is brought about through 
the inhibition of 5-HT3 receptors present both centrally 
(medullary chemoreceptor zone) and peripherally (GI 
tract).Glycerin, Castor oil and Dibutyl phthalate were 
used as plasticizer in varying amount. Sucrose coating 
was given to the chewing gum pieces. Trial runs were 
performed using plasticizers in combination. When 
plasticizers were used in combination, it was observed 
that the gum formulations formed were very sticky.
3, 4
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MATERIALS AND METHODS 
Dolasetron was gift sample of Manus Aktteva 
Biopharma LLP, Ahmedabad, India and synthetic gum 
base from Amber Confectionaries Pvt. Ltd. Sucrose, 
sorbitol, magnesium stearate, talc, flavor and color were 
purchased from Lobachemi chemicals Pvt. Ltd, India. 
All other chemicals/solvents used were of analytical 
grade. 
Preparation of Medicated Chewing Gum
 
All ingredients were weighed accurately as shown in 
formulation table 1. Molten mass of synthetic gum base 
was prepared and plasticizer was mixed thoroughly in 
porcelain dish. The dish was kept on water bath and 
temperature was maintained at about 35-45
o
 C. Drug 
Dolasetron was then added to above mass. 
Corresponding amount of Sucrose and mannitol was 
added to above mixture with continuous stirring up to 30 
min. Finally the adequate amount of flavor was 
incorporated in the mixture. The mass was poured in to 
the mould and was allowed to cool at room temperature. 
The gum pieces were removed.
4, 5, 8 
Coating of MCG was done by liquid coating solution of 
sucrose. The coating solution was sprayed uniformly. 
Coating was dried in hot warm air in temperature range 
27
0
C to 38
0
C. After cooling chewing gum pieces were 
wrapped properly. 
Physical evaluation of drug and synthetic gum base 
Preliminary studies 
Physical evaluation of medicated chewing gum
 
The formulated chewing gum were evaluated for various 
physicochemical parameters including color, softening 
point, stickiness, weight variation, plasticity/hardness, 
percentage drug content and percentage cumulative in-
vitro drug release. 
RESULTS AND DISCUSSION 
Physical evaluation of gum base 
1. Color: Color of synthetic gum base is Pale yellow 
observe visually. 
2. Softening point: Softening point of synthetic gum 
base was observed by heating the base in Petri dish. 
The temperature at which it starts melting is the 
softening point of that base. It was found to be 55-
60
0
C. 
3. Solubility studies of synthetic gum base 
As the gum has showed very negligible solubility in 
artificial saliva and phosphate buffer, it can be 
concluded that the procured synthetic gum base was the 
best for use as base for medicated chewing gum 
preparation. 
Table 1: Solubility studies 
Sr. 
no. 
Solvent Solubility(gm) / 10 ml 
1 Alcohol Up to 2 gm 
2 Chloroform Up to 17 gm 
3 Acetone Soluble 
4 Water Slightly soluble 
5 Artificial saliva Up to 1 gm 
 
Physical evaluation of medicated chewing gum 
The formulated medicated chewing gum was evaluated 
physically for following parameters and is mentioned. 
1. Color: The color of MCG formulation was observed 
visually and all the batches were light brown in color 
which in acceptable limit. 
2. Melting point: Melting point of drug was found to 
be 276-279°C which is in standard range of 276- 
278°C. 
3. Stickiness: The formulated medicated chewing gum 
was placed on plain surface. A mass of 250 gm was 
hammered on it up to 10 min. the frequency of 
hammering was about 30/min. None of the batch 
stuck to hammer or surface. 
4. Weight variation: Chewing gum from each batch 
was individually weighed on analytical balance, the 
average weight and standard deviation were 
calculated which was found in acceptable limit.
3 
5. Plasticity/hardness: Hardness of chewing gum was 
determined by Monsanto hardness tester and the 
average hardness and standard deviation were 
reported.
3 
Percentage drug content: Chewing gum was 
manually divided in to pieces and transferred into 
separating funnel containing 10 ml of 
dichloromethane. Separating funnel was shaken for 
10 – 15 minutes so as to disperse the chewing mass. 
The turbid solution was shaken simultaneously with 
50 ml distill water for 15 minutes for dissolving the 
drug in to it. Separating funnel was kept undisturbed 
for 15 minutes for separation of the two phases. The 
aqueous phase was collected and filtered through 
whatman filtered papers grade 41. Filtrate was 
sufficiently diluted and estimated for the drug 
content at 285 nm in UV spectrophotometer. Same 
procedure was repeated for three times.
 
Stability Studies of synthetic gum base 
Stability studies of synthetic gum base: 10 gm of 
synthetic gum base was stored in bottle at 50º C for 
30 days. After 30 days the gum was examined for 
natural ageing and physical nature. 
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Table 2: Stability Studies of Synthetic Gum Base 
S. No. Properties Observations 
1 Color    (before ageing) Off white- pale yellow 
2 Color    (after ageing) Pale yellow 
3 Softening range     (before ageing) 85- 90°C 
4 Softening range     (after ageing) 86- 88°C 
 
UV Spectroscopy 
λmax of Dolasetron was found to be 285 nm in artificial saliva solution having pH 6.4.  
 
Figure 1: Calibration curve of Dolasetron. 
 
In vitro dissolution studies
 
In order to study the in vitro dissolution pattern from 
chewing gums, it was necessary to design an apparatus, 
which could give same impact of mastication on MCG. 
This was necessary in order to mimic the human 
mastication. After an extensive literature survey and 
discussion with guide it was decided to modify the 
disintegration test apparatus and fabricate suitable 
chewing gum apparatus. Release measurements were 
performed using Lab fabricated medicated chewing gum 
test apparatus at 50 rpm. In each flask a 900 ml of 
artificial saliva pH 6.4 was filled. The temperature was 
maintained at 37±0.5°C. At predetermined time intervals 
(5, 10, 15, 20, 25, 30 and 35 min) absorbance were 
recorded spectrophotometrically at 285 nm and the 
percentage of drug released was determined as a function 
of time. 
 
Figure 2: Lab fabricated Medicated Chewing Gum 
apparatus with Die and punch. 
 
 
Table 3: Formulation Table. 
S. No Ingredients 
Percentage (%w/w) 
MCG I MCG II MCG III MCG IV 
1 Synthetic gum base 25 35 45 55 
2 Drug 1% 1% 1% 1% 
3 Sorbitol 14.6 14.6 14.6 14.6 
4 Sucrose 56 46 36 26 
5 Flavor 0.6 0.6 0.6 0.6 
 6 Magnesium stearate 0.2 0.2 0.2 0.2 
7 Talc 2.364 2.364 2.364 2.364 
8 Color Q.S Q.S Q.S Q.S 
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Table 04: Cumulative % Drug Release. 
S. No. Time(min) % CUMULATIVE DRUG RELEASE± SD 
MCG I MCG II MCG III MCG IV 
1 0 0 0 0 0 
2 2 30.2±0.90 23.4±0.29 28.8±0.16 32.4±0.40 
3 4 50.41±0.53 36.78±0.32 42.12±0.35 42.54±0.24 
4 6 57.51±0.20 45.36±0.35 50.62±0.20 48.12±0.32 
5 8 66.07±0.17 53.67±0.32 57.43±0.33 59.03±0.17 
6 10 69.56±0.28 62.34±0.57 65.36±0.47 66.23±0.03 
7 12 73.74±0.27 74.62±0.42 69.32±0.17 70.50±0.26 
8 15 78.98±0.53 86.34±0.35 72.33±0.33 74.06±0.41 
9 20 83.28±0.20 90.08±0.15 79.66±0.27 82.43±0.06 
10 25 89.12±0.16 96.34±0.24 88.64±0.34 85.21±0.36 
11 30 94.56±0.31 99.43±0.32 96.45±0.36 92.45±0.12 
 
CONCLUSION 
Medicated chewing gum (MCG) is solid, single dose 
preparations with a base consisting mainly of gums that are 
intended to be chewed but not swallowed. Medicated 
chewing gum (MCG) is a novel drug delivery system 
containing masticatory gum base with pharmacologically 
active ingredient and intended to use for local treatment of 
mouth diseases or systemic absorption through oral mucosa.  
Furthermore, in case of buccal absorption, it is likely that the 
dose could be decreased due to the avoidance of first pass 
metabolism, and thus, fewer side effects will be seen. As the 
fear of side effects is predominant among patients, a 
Medicated Chewing gum formulation with lesser amount of 
active ingredient is likely to be favored by the patients. 
Antiemetic drug Metoclopramide, Domperidone, Cisapride 
(prokinetic drug), Neuroleptic drug, Chlorpromazine, 
Prochlorperazine, Haloperidol, 5-HT3 antagonists 
Ondansetron are less suitable for treatment of motion 
sickness, they are more suitable for emesis induced by 
cytotoxic drug or emesis caused due to post operative 
vomiting. Diphenhydramine Hydrochloride based on its 
higher salivary solubility and fewer side effects (no extra 
pyramidal effect) is the suitable candidate for formulation of 
MCG for prevention of motion sickness. 
MCG II formulation was considered to be best optimized 
formula which consists of synthetic gum base (45%), 
sorbitol (14.6%), sucrose (46%) etc. which shows first slow 
release the fast release in the phosphate buffer saline (pH 
6.8). The cumulative drug release of MCG II formulation 
was found to be 99.43 %. From this study we can conclude 
that the medicated chewing formulation can be better choice 
in the coming years which provides several benefits and also 
benefits commercially. 
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